<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39558820</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2001-3078</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of extracellular vesicles</Title><ISOAbbreviation>J Extracell Vesicles</ISOAbbreviation></Journal><ArticleTitle>Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19.</ArticleTitle><Pagination><StartPage>e70001</StartPage><MedlinePgn>e70001</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70001</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/jev2.70001</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and has been related to more than 7 million deaths globally since 2019. The association of high levels of IL-6 with severe cases led to the early evaluation of the anti-IL6 inhibitor tocilizumab as a potential treatment, which unfortunately failed to improve survival in many trials. Moreover, little is known about the development of COVID-19 sequelae, and biomarkers are needed to understand and anticipate these processes. Because extracellular vesicles (EVs) play an important role in viral infection and immune response, they could potentially serve as predictive and prognostic biomarkers. We isolated EVs from 39 patients with severe COVID-19, from which 29 received tocilizumab and 10 were considered controls. Blood samples, which were collected at hospitalisation before treatment, at Day 7, and Day 15 during follow-up, were assessed by immunoblot for longitudinal expression of spike (S) and nucleocapsid (N) proteins. Dynamic expression was calculated and compared with clinicopathological and experimental variables. Expression of EV S was validated by immunogold and imaging flow-cytometry, revealing an enrichment in CD9+ EVs. As a result, decreasing expression of EV viral proteins was observed in patients treated with tocilizumab. Moreover, higher increase in EV S was observed in patients with lower antibody response, hyperfibrinogenemia, lower respiratory function, higher blood pressure and shorter outcomes. These findings lay the foundation for future studies characterizing the role of EVs in multiorgan assessment and identifying biomarkers in patients with severe COVID-19 and possible long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Journal of Extracellular Vesicles published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Miguel-Perez</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2822-4466</Identifier><AffiliationInfo><Affiliation>Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arroyo-Hernandez</LastName><ForeName>Marisol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Salvia</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunasekaran</LastName><ForeName>Muthukumar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Surgery and Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering</LastName><ForeName>Edward M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avila</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebru</LastName><ForeName>Etse</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becerril-Vargas</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Institute of Respiratory Diseases, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monraz-Perez</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Institute of Respiratory Diseases, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saharia</LastName><ForeName>Kapil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grazioli</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Program in Trauma, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCurdy</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0001-5319-0475</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frieman</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miorin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona</LastName><ForeName>Andr&#xe9;s F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Institute for Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Sastre</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaushal</LastName><ForeName>Sunjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Surgery and Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Fred R</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atanackovic</LastName><ForeName>Djordje</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahoo</LastName><ForeName>Susmita</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7279-1564</Identifier><AffiliationInfo><Affiliation>Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrieta</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolfo</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54CA260560</GrantID><Agency>NCI-SERONET</Agency><Country/></Grant><Grant><GrantID>CEIRR</GrantID><Agency>NIAID-funded Center of Excellence for Influenza Research and Response</Agency><Country/></Grant><Grant><GrantID>75N93021C00014</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK125856</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL140469</GrantID><Agency>NIH-NHLBI</Agency><Country/></Grant><Grant><GrantID>R01HL148786</GrantID><Agency>NIH-NHLBI</Agency><Country/></Grant><Grant><GrantID>U19AI135972</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AI168631</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Evox Therapeutics, UK</Agency><Country/></Grant><Grant><Agency>CRIPT (Center for Research on Influenza Pathogenesis and Transmission)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Extracell Vesicles</MedlineTA><NlmUniqueID>101610479</NlmUniqueID><ISSNLinking>2001-3078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705834">nucleocapsid phosphoprotein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="Y">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">extracellular vesicles</Keyword><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">nucleocapsid</Keyword><Keyword MajorTopicYN="N">spike protein</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList><CoiStatement>M. Arroyo&#x2010;Hernandez reports receiving personal fees from Astra Zeneca, Bristol, and Roche outside the submitted work A. Russo reports advisory board role/consultancy from AstraZeneca, MSD, Novartis, Pfizer, BMS, Takeda, and Amgen; compensated activity for editorial projects from AstraZeneca, MSD, Novartis, and Roche unrelated to the current work. A. F. Cardona discloses financial research support from Merck Sharp &amp; Dohme, Boehringer Ingelheim, Roche, Bristol&#x2010;Myers Squibb, Foundation Medicine, Roche Diagnostics, Thermo Fisher, Broad Institute, BioNTech, Amgen, Flatiron Health, Teva Pharma, Rochem Biocare, Bayer, INQBox and The Foundation for Clinical and Applied Cancer Research&#x2014;FICMAC. Advisor role to EISAI, Merck Serono, Jannsen Pharmaceutical, Merck Sharp &amp; Dohme, Boehringer Ingelheim, Roche, Bristol&#x2010;Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant Health, Illumina, and Foundation for Clinical and Applied Cancer Research&#x2014;FICMAC. The A. Garcia&#x2010;Sastre laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson &amp; Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N&#x2010;fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck, outside of the reported work. He has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta, outside of the reported work. He has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, Astrazeneca and Novavax. He is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work. F. R. Hirsch reports advisory boards consultancy for Bristol&#x2010;Myers Squibb, AstraZeneca/Daiichi, Sanofi/Regeneron, Novartis, Amgen, OncoCyte, Genentech, and Nectin Therapeutics, Novocure, NextCure, Merus, G1 Therapeutics, Oncohost, Agilent/DAKO. Patent (Through University of Colorado); EGFR protein&#x2010; and EGFR gene copy number expression as predictive biomarkers for EGFR&#x2010;directed therapy. O. Arrieta reports receiving personal fees from Pfizer, Lilly, Merck, and Bristol&#x2010;Myers Squibb and grants and personal fees from AstraZeneca, Boehringer Ingelheim, and Roche outside the submitted work. Other authors declare that they have no competing interests. C. Rolfo has received speaker honoraria from AstraZeneca, Roche and MSD, advisory board honoraria from Inivata, Archer, Boston Pharmaceuticals, MD Serono and Novartis, Bayer, Invitae, Regeneron, Janssen, Bostongene, Novocure, Scientific Advisory Board member of Imagene, and institutional research funding from LCRF&#x2010; Pfizer and NCRF, non&#x2010;renumerated research support from GuardantHealth and Foundation Medicine. He has non&#x2010;renumerated leadership roles at the International Society of Liquid Biopsy (ISLB), the International Association for Study of Lung Cancer (IASLC), the European School of Oncology (ESO), and Oncology Latin American Association (OLA). The rest of the authors declares no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39558820</ArticleId><ArticleId IdType="pmc">PMC11574309</ArticleId><ArticleId IdType="doi">10.1002/jev2.70001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>RECOVERY Collaborative Group . (2021). Tocilizumab in patients admitted to hospital with COVID&#x2010;19 (RECOVERY): A randomised, controlled, open&#x2010;label, platform trial. Lancet, 397, 1637&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpek, M. (2022). Does COVID&#x2010;19 cause hypertension? Angiology, 73, 682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260192</ArticleId><ArticleId IdType="pubmed">34889662</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanackovic, D. , Avila, S. V. , Lutfi, F. , de Miguel&#x2010;Perez, D. , Fan, X. , Sanchez&#x2010;Petitto, G. , Vander Mause, E. , Siglin, J. , Baddley, J. , Mannuel, H. D. , Alkhaldi, H. , Hankey, K. G. , Lapidus, R. , Kleinberg, M. , Rabin, J. , Shanholtz, C. , Rolfo, C. , Rapoport, A. P. , Dahiya, S. , &amp; Luetkens, T. (2021). Deep dissection of the antiviral immune profile of patients with COVID&#x2010;19. Communications biology, 4, 1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677724</ArticleId><ArticleId IdType="pubmed">34916602</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbi, C. , Burrello, J. , Bolis, S. , Lazzarini, E. , Biemmi, V. , Pianezzi, E. , Burrello, A. , Caporali, E. , Grazioli, L. G. , Martinetti, G. , Fusi&#x2010;Schmidhauser, T. , Vassalli, G. , Melli, G. , &amp; Barile, L. (2021). Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS&#x2010;CoV&#x2010;2 infection. EBioMedicine, 67, 103369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8104913</ArticleId><ArticleId IdType="pubmed">33971404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal, S. , Perincheri, S. , Fleming, T. , Poulson, C. , Tiffany, B. , Bremner, R. M. , &amp; Mohanakumar, T. (2021). Cutting edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer&#x2010;BioNTech) vaccination prior to development of antibodies: A novel mechanism for immune activation by mRNA vaccines. Journal of immunology, 207, 2405&#x2013;2410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11073804</ArticleId><ArticleId IdType="pubmed">34654691</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzas, E. I. (2022). The roles of extracellular vesicles in the immune system. Nature Reviews Immunology, 23, 236&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361922</ArticleId><ArticleId IdType="pubmed">35927511</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzas, E. I. , Gy&#xf6;rgy, B. , Nagy, G. , Falus, A. , &amp; Gay, S. (2014). Emerging role of extracellular vesicles in inflammatory diseases. Nature Reviews Rheumatology, 10, 356&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">24535546</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, X. , Li, H. , Song, H. , Wang, J. , Zhang, X. , Han, P. , &amp; Wang, X. (2022). Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS&#x2010;CoV&#x2010;2. Journal of Extracellular Vesicles, 11, e12288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9712136</ArticleId><ArticleId IdType="pubmed">36450704</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock, V. , Mahajan, A. , Spikes, L. , Krishnamachary, B. , Ram, A. K. , Kumar, A. , Chen, L. , Chalise, P. , &amp; Dhillon, N. K. (2023). Persistent circulation of soluble and extracellular vesicle&#x2010;linked Spike protein in individuals with postacute sequelae of COVID&#x2010;19. Journal of Medical Virology, 95, e28568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>de Miguel&#x2010;Perez, D. , Ortega, F. G. , Tejada, R. G. , Mart&#xed;nez&#x2010;&#xda;nica, A. , Peterson, C. B. , Russo, A. , Gunasekaran, M. , Cardona, A. F. , Amezcua, V. , Lorente, J. A. , Exp&#xf3;sito Hern&#xe1;ndez, J. , Rolfo, C. , &amp; Serrano, M. J. (2023). Baseline extracellular vesicle miRNA&#x2010;30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. Biomarker Research, 11, 98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10652484</ArticleId><ArticleId IdType="pubmed">37968730</ArticleId></ArticleIdList></Reference><Reference><Citation>de Miguel&#x2010;Perez, D. , Russo, A. , Arrieta, O. , Ak, M. , Barron, F. , Gunasekaran, M. , Mamindla, P. , Lara&#x2010;Mejia, L. , Peterson, C. B. , Er, M. E. , Peddagangireddy, V. , Buemi, F. , Cooper, B. , Manca, P. , Lapidus, R. G. , Hsia, R. C. , Cardona, A. F. , Naing, A. , Kaushal, S. , &#x2026; Rolfo, C. (2022). Extracellular vesicle PD&#x2010;L1 dynamics predict durable response to immune&#x2010;checkpoint inhibitors and survival in patients with non&#x2010;small cell lung cancer. Journal of Experimental &amp; Clinical Cancer Research : CR, 41, 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161571</ArticleId><ArticleId IdType="pubmed">35650597</ArticleId></ArticleIdList></Reference><Reference><Citation>de Miguel&#x2010;Perez, D. , Russo, A. , Gunasekaran, M. , Buemi, F. , Hester, L. , Fan, X. , Carter&#x2010;Cooper, B. A. , Lapidus, R. G. , Peleg, A. , Arroyo&#x2010;Hern&#xe1;ndez, M. , Cardona, A. F. , Naing, A. , Hirsch, F. R. , Mack, P. C. , Kaushal, S. , Serrano, M. J. , Adamo, V. , Arrieta, O. , &amp; Rolfo, C. (2023). Baseline extracellular vesicle TGF&#x2010;&#x3b2; is a predictive biomarker for response to immune checkpoint inhibitors and survival in non&#x2010;small cell lung cancer. Cancer, 129, 521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">36484171</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, X. J. , Tang, K. , Wang, Z. , He, S. , &amp; Luo, Z. (2024). Impacts of inflammatory cytokines variants on systemic inflammatory profile and COVID&#x2010;19 severity. Journal of Epidemiology and Global Health, 14(2), 363&#x2013;378. 10.1007/S44197-024-00204-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S44197-024-00204-W</ArticleId><ArticleId IdType="pmc">PMC11176143</ArticleId><ArticleId IdType="pubmed">38376765</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, H. , Du, Z. , Wang, L. , Wang, H. , Jia, M. , Zhang, C. , Liu, Y. , Zhang, C. , Zhang, Y. , Zhang, R. , Zhang, S. , Zhang, N. , Ma, Z. , Chen, C. , Liu, W. , Zeng, H. , Gao, G. F. , Hou, X. , &amp; Bi, Y. (2024). Fulminant myocarditis induced by SARS&#x2010;CoV&#x2010;2 infection without severe lung involvement: Insights into COVID&#x2010;19 pathogenesis. Journal of Genetics and Genomics, 51, 608&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">38447818</ArticleId></ArticleIdList></Reference><Reference><Citation>Earnest, J. T. , Hantak, M. P. , Li, K. , McCray, P. B. Jr , Perlman, S. , &amp; Gallagher, T. (2017). The tetraspanin CD9 facilitates MERS&#x2010;coronavirus entry by scaffolding host cell receptors and proteases. PLoS pathogens, 13(7), e1006546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552337</ArticleId><ArticleId IdType="pubmed">28759649</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald, W. , Freeman, M. L. , Lederman, M. M. , Vasilieva, E. , Romero, R. , &amp; Margolis, L. (2018). A system of cytokines encapsulated in extracellular vesicles. Scientific Reports, 8, 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997670</ArticleId><ArticleId IdType="pubmed">29895824</ArticleId></ArticleIdList></Reference><Reference><Citation>George, M. S. , Sanchez, J. , Rollings, C. , Fear, D. , Irving, P. , Sinclair, L. V. , &amp; Schurich, A. (2023). Extracellular vesicles in COVID&#x2010;19 convalescence can regulate T cell metabolism and function. Iscience, 26, 107280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10371842</ArticleId><ArticleId IdType="pubmed">37520724</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerard, L. , Lecocq, M. , Bouzin, C. , Hoton, D. , Schmit, G. , Pereira, J. P. , Montiel, V. , Plante&#x2010;Bordeneuve, T. , Laterre, P. F. , &amp; Pilette, C. (2021). Increased angiotensin&#x2010;converting enzyme 2 and loss of alveolar Type II cells in COVID&#x2010;19&#x2010;related acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 204, 1024&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8663012</ArticleId><ArticleId IdType="pubmed">34449302</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP&#x2010;CAP Investigators . Gordon, A. C. , Mouncey, P. R. , Al&#x2010;Beidh, F. , Rowan, K. M. , Nichol, A. D. , Arabi, Y. M. , Annane, D. , Beane, A. , van Bentum&#x2010;Puijk, W. , Berry, L. R. , Bhimani, Z. , Bonten, M. J. M. , Bradbury, C. A. , Brunkhorst, F. M. , Buzgau, A. , Cheng, A. C. , Detry, M. A. , Duffy, E. J. , Estcourt, L. J. , &#x2026; Derde, L. P. G. . (2021). Interleukin&#x2010;6 receptor antagonists in critically ill patients with Covid&#x2010;19. The New England Journal of Medicine, 384, 1491&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff, D. , Sun, A. , Ssentongo, A. E. , Ba, D. M. , Parsons, N. , Poudel, G. R. , Lekoubou, A. , Oh, J. S. , Ericson, J. E. , Ssentongo, P. , &amp; Chinchilli, V. M. (2021). Short&#x2010;term and long&#x2010;term rates of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection: A systematic review. JAMA Network Open, 4(10), e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanpour, M. , Rezaie, J. , Nouri, M. , &amp; Panahi, Y. (2020). The role of extracellular vesicles in COVID&#x2010;19 virus infection. Infection, Genetics and Evolution, 85, 104422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293471</ArticleId><ArticleId IdType="pubmed">32544615</ArticleId></ArticleIdList></Reference><Reference><Citation>He, T. , Ling, J. , &amp; Yang, J. (2023). Tocilizumab&#x2010;induced hypofibrinogenemia in patients with systemic&#x2010;onset juvenile idiopathic arthritis. Scientific Reports, 13, 9050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10239447</ArticleId><ArticleId IdType="pubmed">37270663</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamachary, B. , Cook, C. , Kumar, A. , Spikes, L. , Chalise, P. , &amp; Dhillon, N. K. (2021). Extracellular vesicle&#x2010;mediated endothelial apoptosis and EV&#x2010;associated proteins correlate with COVID&#x2010;19 disease severity. Journal of Extracellular Vesicles, 10(9), e12117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8254805</ArticleId><ArticleId IdType="pubmed">34262673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannigan, J. , &amp; Erdbruegger, U. (2017). Imaging flow cytometry for the characterization of extracellular vesicles. Methods, 112, 55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">27721015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahkuri, S. , Becker, T. , Schueller, V. , Massberg, S. , &amp; Bauer&#x2010;Mehren, A. (2021). Prior fluid and electrolyte imbalance is associated with COVID&#x2010;19 mortality. Communications Medicine, 1, 51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9053234</ArticleId><ArticleId IdType="pubmed">35602191</ArticleId></ArticleIdList></Reference><Reference><Citation>Parotto, M. , Gy&#xf6;ngy&#xf6;si, M. , Howe, K. , Myatra, S. N. , Ranzani, O. , Shankar&#x2010;Hari, M. , &amp; Herridge, M. S. (2023). Post&#x2010;acute sequelae of COVID&#x2010;19: understanding and addressing the burden of multisystem manifestations. The Lancet Respiratory Medicine, 11(8), 739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">37475125</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesce, E. , Manfrini, N. , Cordiglieri, C. , Santi, S. , Bandera, A. , Gobbini, A. , Gruarin, P. , Favalli, A. , Bombaci, M. , Cuomo, A. , Collino, F. , Cricr&#xec;, G. , Ungaro, R. , Lombardi, A. , Mangioni, D. , Muscatello, A. , Aliberti, S. , Blasi, F. , Gori, A. , &#x2026; Grifantini, R. (2022). Exosomes recovered from the plasma of COVID&#x2010;19 patients expose SARS&#x2010;CoV&#x2010;2 spike&#x2010;derived fragments and contribute to the adaptive immune response. Frontiers in Immunology, 12, 785941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801440</ArticleId><ArticleId IdType="pubmed">35111156</ArticleId></ArticleIdList></Reference><Reference><Citation>Rautaniemi, K. , Zini, J. , L&#xf6;fman, E. , Saari, H. , Haapalehto, I. , Laukka, J. , Vesam&#xe4;ki, S. , Efimov, A. , Yliperttula, M. , Laaksonen, T. , Vuorimaa&#x2010;Laukkanen, E. , &amp; Lisitsyna, E. S. (2021). Addressing challenges in the removal of unbound dye from passively labelled extracellular vesicles. Nanoscale Advances, 4, 226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417910</ArticleId><ArticleId IdType="pubmed">36132960</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas, I. O. , Br&#xe4;u, N. , Waters, M. , Go, R. C. , Hunter, B. D. , Bhagani, S. , Skiest, D. , Aziz, M. S. , Cooper, N. , Douglas, I. S. , Savic, S. , Youngstein, T. , Del Sorbo, L. , Cubillo Gracian, A. , De La Zerda, D. J. , Ustianowski, A. , Bao, M. , Dimonaco, S. , Graham, E. , &#x2026; Malhotra, A. (2021). Tocilizumab in hospitalized patients with severe Covid&#x2010;19 pneumonia. The New England Journal of Medicine, 384, 1503&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy, B. , &amp; Runa, S. A. (2022). SARS&#x2010;CoV&#x2010;2 infection and diabetes: Pathophysiological mechanism of multi&#x2010;system organ failure. World Journal of Virology, 11, 252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9523319</ArticleId><ArticleId IdType="pubmed">36188734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushworth, C. A. , Guy, J. L. , &amp; Turner, A. J. (2008). Residues affecting the chloride regulation and substrate selectivity of the angiotensin&#x2010;converting enzymes (ACE and ACE2) identified by site&#x2010;directed mutagenesis. The FEBS Journal, 275, 6033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163990</ArticleId><ArticleId IdType="pubmed">19021774</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama, C. , Han, J. , Yau, L. , Reiss, W. G. , Kramer, B. , Neidhart, J. D. , Criner, G. J. , Kaplan&#x2010;Lewis, E. , Baden, R. , Pandit, L. , Cameron, M. L. , Garcia&#x2010;Diaz, J. , Ch&#xe1;vez, V. , Mekebeb&#x2010;Reuter, M. , Lima de Menezes, F. , Shah, R. , Gonz&#xe1;lez&#x2010;Lara, M. F. , Assman, B. , Freedman, J. , &amp; Mohan, S. V. (2021). Tocilizumab in patients hospitalized with Covid&#x2010;19 pneumonia. The New England Journal of Medicine, 384, 20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Somiya, M. (2022). Comment on &#x2018;cutting edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer&#x2010;BioNTech) vaccination prior to development of antibodies: A novel mechanism for immune activation by mRNA vaccines&#x2019;. Journal of Immunology, 208, 1833&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pubmed">35418503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet, D. R. , Freeman, M. L. , &amp; Zidar, D. A. (2023). Immunohematologic biomarkers in COVID&#x2010;19: Insights into pathogenesis, prognosis, and prevention. Pathogens &amp; Immunity, 8, 17&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10324469</ArticleId><ArticleId IdType="pubmed">37427016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tertel, T. , Tomi&#x107;, S. , &#x110;oki&#x107;, J. , Radojevi&#x107;, D. , Stevanovi&#x107;, D. , Ili&#x107;, N. , Giebel, B. , &amp; Kosanovi&#x107;, M. (2022). Serum&#x2010;derived extracellular vesicles: Novel biomarkers reflecting the disease severity of COVID&#x2010;19 patients. Journal of Extracellular Vesicles, 11, e12257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9451525</ArticleId><ArticleId IdType="pubmed">35979935</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyer, Z. , Alhusaini, N. , Tabler, C. O. , Sweet, T. , de Carvalho, K. I. L. , Schlatzer, D. M. , Carias, L. , King, C. L. , Matreyek, K. , &amp; Tilton, J. C. (2021). Extracellular Vesicles Carry SARS&#x2010;CoV&#x2010;2 Spike Protein and Serve as Decoys for Neutralizing Antibodies. Journal of Extracellular Vesicles, 10, e12112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213968</ArticleId><ArticleId IdType="pubmed">34188786</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh, J. A. , Goberdhan, D. C. I. , O'Driscoll, L. , Buzas, E. I. , Blenkiron, C. , Bussolati, B. , Cai, H. , Di Vizio, D. , Driedonks, T. A. P. , Erdbr&#xfc;gger, U. , Falcon&#x2010;Perez, J. M. , Fu, Q. L. , Hill, A. F. , Lenassi, M. , Lim, S. K. , Mahoney, M. G. , Mohanty, S. , M&#xf6;ller, A. , Nieuwland, R. , &#x2026; Witwer, K. W. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 13, e12404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10850029</ArticleId><ArticleId IdType="pubmed">38326288</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, B. , Pan, X. , Luo, R. H. , Shen, X. , Li, S. , Wang, Y. , Zuo, X. , Wu, Y. , Guo, Y. , Xiao, G. , Li, Q. , Long, X. Y. , He, X. Y. , Zheng, H. Y. , Lu, Y. , Pang, W. , Zheng, Y. T. , Li, J. , Zhang, L. K. , &amp; Gao, Z. (2023). Extracellular vesicles mediate antibody&#x2010;resistant transmission of SARS&#x2010;CoV&#x2010;2. Cell Discovery, 9, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9821354</ArticleId><ArticleId IdType="pubmed">36609376</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, V. , Fisher, M. , Hou, W. , Zhang, L. , &amp; Duong, T. Q. (2023). Incidence of New&#x2010;onset hypertension post&#x2010;COVID&#x2010;19: Comparison with influenza. Hypertension, 80, 2135&#x2013;2148.</Citation><ArticleIdList><ArticleId IdType="pubmed">37602375</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>